Marina Ziehn
Overview
Explore the profile of Marina Ziehn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Craner M, Al Malik Y, Babtain F, Alshamrani F, Alkhawajah M, Alfugham N, et al.
Neurol Ther
. 2022 Sep;
11(4):1457-1473.
PMID: 36048334
Treatment-pattern data suggest that some patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) may not be receiving optimal treatment. A virtual meeting of ten expert Saudi...
2.
Torres J, Roodselaar J, Sealey M, Ziehn M, Bigaud M, Kneuer R, et al.
Front Immunol
. 2022 Aug;
13:814064.
PMID: 35967378
Approval of B-cell-depleting therapies signifies an important advance in the treatment of multiple sclerosis (MS). However, it is unclear whether the administration route of anti-CD20 monoclonal antibodies (mAbs) alters tissue...
3.
Mao-Draayer Y, Cohen J, Bar-Or A, Han M, Singer B, Williams I, et al.
Mult Scler J Exp Transl Clin
. 2022 Aug;
8(3):20552173221115023.
PMID: 35936922
Background: Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood. Objective: Investigate fingolimod's temporal effects on immune cell...
4.
Burtchell J, Clemmons D, Clemmons J, Sabutis T, Rosenberg A, Graves J, et al.
Neurol Ther
. 2022 May;
11(3):955-979.
PMID: 35608740
Introduction: The mechanisms of action of disease-modifying therapies (DMTs) for multiple sclerosis (MS) are complex and involve an interplay of immune system components. People with MS (PwMS) may lack a...
5.
Galetta K, Deshpande C, Healy B, Glanz B, Ziehn M, Saxena S, et al.
Ann Clin Transl Neurol
. 2021 Jan;
8(3):631-638.
PMID: 33492760
Objective: Serum neurofilament light (sNfL) is a promising new biomarker in multiple sclerosis (MS). We explored the relationship between sNfL and health outcomes and resource use in MS patients. Methods:...
6.
Nicholas J, Halpern R, Ziehn M, Peterson-Brandt J, Leszko M, Deshpande C
J Med Econ
. 2020 Apr;
23(8):885-893.
PMID: 32338098
The study evaluated the real-world cost of treatment in multiple sclerosis (MS) patients initiating infused disease-modifying-therapies (DMT) in the United States. This retrospective cohort study using administrative claims data included...
7.
Fox E, Lublin F, Wolinsky J, Cohen J, Williams I, Meng X, et al.
Neurol Neuroimmunol Neuroinflamm
. 2019 Sep;
6(6).
PMID: 31511330
Objective: To evaluate lymphocyte counts and incidences of infections in patients with primary progressive MS (PPMS) receiving fingolimod 0.5 mg/d or placebo over 5 years during the INFORMS study, to...